77837-09-3

Basic information

• Product Name: METHYL 5-CARBOXY-N-PHENYL-2-1H-PYRIDONE
• Synonyms: 1,6-Dihydro-6-oxo-1-phenyl-nicotinic Acid Methyl Ester;Methyl 6-Oxo-1-phenyl-1,6-dihydropyridine-3-carboxylate;6-Oxo-1-phenyl-1,6-dihydro-pyridine-3-carboxylic acid methyl ester
• CAS NO: 77837-09-3
• Molecular Formula: C₁₃H₁₁NO₃
• Molecular Weight: 229.23
• Product Categories: Aromatics Compounds;Aromatics;Metabolites;Metabolites & Impurities
• Mol File: 77837-09-3.mol
• Article Data: 8

Chemical Properties

• Melting Point: 160-162 °C
• Boiling Point: 370.016°C at 760 mmHg
• Flash Point: 177.58°C
• Appearance: /
• Density: 1.271g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.596
• Storage Temp.: Sealed in dry,Room Temperature
• PKA: -1.40±0.63(Predicted)
• CAS DataBase Reference: METHYL 5-CARBOXY-N-PHENYL-2-1H-PYRIDONE(CAS DataBase Reference)
• NIST Chemistry Reference: METHYL 5-CARBOXY-N-PHENYL-2-1H-PYRIDONE(77837-09-3)
• EPA Substance Registry System: METHYL 5-CARBOXY-N-PHENYL-2-1H-PYRIDONE(77837-09-3)

Safety Data

• Hazardous Substances Data: 77837-09-3(Hazardous Substances Data)

Usage

Description

METHYL 5-CARBOXY-N-PHENYL-2-1H-PYRIDONE is a white solid that is a metabolite of Pirfenidone, a drug used for the treatment of patients with kidney disease who also have diabetes. METHYL 5-CARBOXY-N-PHENYL-2-1H-PYRIDONE possesses unique chemical properties that make it a valuable component in the pharmaceutical industry.

Uses

Used in Pharmaceutical Industry:
METHYL 5-CARBOXY-N-PHENYL-2-1H-PYRIDONE is used as an active pharmaceutical ingredient (API) for the development of new drugs targeting kidney disease in patients with diabetes. Its role as a metabolite of Pirfenidone contributes to its potential therapeutic effects in managing and treating this specific health condition.
Used in Research and Development:
In the field of medical research, METHYL 5-CARBOXY-N-PHENYL-2-1H-PYRIDONE serves as a valuable compound for studying the effects and mechanisms of Pirfenidone in treating kidney disease associated with diabetes. This research can lead to the development of more effective treatments and a better understanding of the underlying causes of the disease.
Used in Drug Formulation:
METHYL 5-CARBOXY-N-PHENYL-2-1H-PYRIDONE can be used as a key component in the formulation of new drugs or drug combinations for the treatment of kidney disease in diabetic patients. Its chemical properties and metabolite status make it a promising candidate for improving the efficacy and safety of existing treatments.
Used in Quality Control and Standardization:
In the pharmaceutical industry, METHYL 5-CARBOXY-N-PHENYL-2-1H-PYRIDONE can be employed as a reference compound for quality control and standardization purposes. Its unique chemical properties and association with Pirfenidone make it an ideal candidate for ensuring the consistency, purity, and potency of drugs targeting kidney disease in diabetic patients.

InChI:InChI=1/C13H11NO3/c1-17-13(16)10-7-8-12(15)14(9-10)11-5-3-2-4-6-11/h2-9H,1H3

Upstream product

• 500-05-0 2H-pyran-2-one-5-carboxylic acid 
• 62-53-3 aniline 
• 6018-41-3 methyl coumalate 
• 66171-50-4 6-oxo-1,6-dihydropyridin-3-carboxylic acid methyl ester 
• 98-80-6 phenylboronic acid 

Downstream Products

• 77837-08-2 6-oxo-1-phenyl-1,6-dihydro-3-pyridinecarboxylic acid 
• 1093952-03-4 5-(hydroxy(methyl-d2))-1-phenylpyridin-2(1H)-one 
• 1392221-04-3 (1-azabicyclo[2.2.2]octan-3-yl)-6-oxo-1-phenyl-3-pyridinecarboxylate 
• 1392221-19-0 6-oxo-1-phenyl-1,6-dihydro-pyridine-3-carbonyl chloride 
• 1392219-90-7 N-(1-azabicyclo[2.2.2]octan-3-yl)-6-oxo-1-phenyl-3-pyridinecarboxamide 

Relevant articles and documents

-

-

PHARMACEUTICAL COMPOSITION COMPRISING PYRIDONE DERIVATIVES

A pyridone derivative compound and a pharmaceutically acceptable salt, isomer, solvate or hydrate thereof, and a preventive or therapeutic pharmaceutical composition for cognitive disorders that includes the pyridone derivative compound or a pharmaceutically acceptable salt, isomer, solvate or hydrate thereof.

Discovery of dap-3 polymyxin analogues for the treatment of multidrug-resistant gram-negative nosocomial infections

We report novel polymyxin analogues with improved antibacterial in vitro potency against polymyxin resistant recent clinical isolates of Acinetobacter baumannii and Pseudomonas aeruginosa. In addition, a human renal cell in vitro assay (hRPTEC) was used to inform structure-toxicity relationships and further differentiate analogues. Replacement of the Dab-3 residue with a Dap-3 in combination with a relatively polar 6-oxo-1-phenyl-1,6-dihydropyridine-3- carbonyl side chain as a fatty acyl replacement yielded analogue 5x, which demonstrated an improved in vitro antimicrobial and renal cytotoxicity profiles relative to polymyxin B (PMB). However, in vivo PK/PD comparison of 5x and PMB in a murine neutropenic thigh model against P. aeruginosa strains with matched MICs showed that 5x was inferior to PMB in vivo, suggesting a lack of improved therapeutic index in spite of apparent in vitro advantages.